Marathon Capital Management Myovant Sciences Ltd. Transaction History

Marathon Capital Management

  • $399 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022
SELL
$14.31 - $23.87 $176,442 - $294,317
-12,330 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$17.07 - $24.56 $29,991 - $43,151
1,757 Added 16.62%
12,330 $280,000
Q1 2021

May 14, 2021
BUY
$20.46 - $25.18 $216,323 - $266,228
10,573 New
10,573 $217,000

Others Institutions Holding MYOV

# of Institutions
6
Shares Held
61.3K
Call Options Held
0
Put Options Held
0
View Full List

About Myovant Sciences Ltd.

MYOV Quotes by TradingView
  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Marathon Capital Management Portfolio

Follow Marathon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Marathon Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email